Between 2000 and 2008, I investigated prior art, freedom-to-operate, infringement evidences and patent portfolios for reputable patent attorneys and life science industry clients, like Roche and BASF.
In 2004, I ad-hoc joined a BASF due diligence team that was preparing a company buy-in as an external expert for analyzing the biosequences portfolio (assets) of the company planned to be acquired.
I locally evaluated the IP relevance of the protein and DNA sequences offered, e.g. by checking for uniqueness and redundancies. I applied in-depth computer-based sequence analysis using algorithms like BLASTx, TBLASTx, FASTA, FASTM, Smith-Waterman, and ClustalW2.
| CLIENT: BASF | PROJECT TIME FRAME: May 2004 |
